These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 28369767)

  • 1. Multiple targets for flecainide action: implications for cardiac arrhythmogenesis.
    Salvage SC; Chandrasekharan KH; Jeevaratnam K; Dulhunty AF; Thompson AJ; Jackson AP; Huang CL
    Br J Pharmacol; 2018 Apr; 175(8):1260-1278. PubMed ID: 28369767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flecainide exerts paradoxical effects on sodium currents and atrial arrhythmia in murine RyR2-P2328S hearts.
    Salvage SC; King JH; Chandrasekharan KH; Jafferji DI; Guzadhur L; Matthews HR; Huang CL; Fraser JA
    Acta Physiol (Oxf); 2015 Jul; 214(3):361-75. PubMed ID: 25850710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flecainide Paradoxically Activates Cardiac Ryanodine Receptor Channels under Low Activity Conditions: A Potential Pro-Arrhythmic Action.
    Salvage SC; Gallant EM; Fraser JA; Huang CL; Dulhunty AF
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.
    Bannister ML; Thomas NL; Sikkel MB; Mukherjee S; Maxwell C; MacLeod KT; George CH; Williams AJ
    Circ Res; 2015 Apr; 116(8):1324-35. PubMed ID: 25648700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.
    Kryshtal DO; Blackwell DJ; Egly CL; Smith AN; Batiste SM; Johnston JN; Laver DR; Knollmann BC
    Circ Res; 2021 Feb; 128(3):321-331. PubMed ID: 33297863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moving in the right direction: elucidating the mechanisms of interaction between flecainide and the cardiac ryanodine receptor.
    Bannister ML; MacLeod KT; George CH
    Br J Pharmacol; 2022 Jun; 179(11):2558-2563. PubMed ID: 34698387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
    Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
    Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How does flecainide impact RyR2 channel function?
    Salvage SC; Huang CL; Fraser JA; Dulhunty AF
    J Gen Physiol; 2022 Sep; 154(9):. PubMed ID: 35713932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights on the mechanism of flecainide in catecholaminergic polymorphic ventricular tachycardia.
    Davidson R; Medeiros M
    J Med Life; 2023 Aug; 16(8):1294-1296. PubMed ID: 38024821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.
    Hilliard FA; Steele DS; Laver D; Yang Z; Le Marchand SJ; Chopra N; Piston DW; Huke S; Knollmann BC
    J Mol Cell Cardiol; 2010 Feb; 48(2):293-301. PubMed ID: 19835880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.
    Liu N; Denegri M; Ruan Y; Avelino-Cruz JE; Perissi A; Negri S; Napolitano C; Coetzee WA; Boyden PA; Priori SG
    Circ Res; 2011 Jul; 109(3):291-5. PubMed ID: 21680895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.
    Yang PC; Moreno JD; Miyake CY; Vaughn-Behrens SB; Jeng MT; Grandi E; Wehrens XH; Noskov SY; Clancy CE
    J Physiol; 2016 Feb; 594(3):567-93. PubMed ID: 26515697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ca2+-dependent modulation of voltage-gated myocyte sodium channels.
    Salvage SC; Habib ZF; Matthews HR; Jackson AP; Huang CL
    Biochem Soc Trans; 2021 Nov; 49(5):1941-1961. PubMed ID: 34643236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of flecainide derivatives on sarcoplasmic reticulum calcium release suggests a lack of direct action on the cardiac ryanodine receptor.
    Bannister ML; Alvarez-Laviada A; Thomas NL; Mason SA; Coleman S; du Plessis CL; Moran AT; Neill-Hall D; Osman H; Bagley MC; MacLeod KT; George CH; Williams AJ
    Br J Pharmacol; 2016 Aug; 173(15):2446-59. PubMed ID: 27237957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses ryanodine receptor function.
    Zhao YT; Valdivia CR; Gurrola GB; Powers PP; Willis BC; Moss RL; Jalife J; Valdivia HH
    Proc Natl Acad Sci U S A; 2015 Mar; 112(13):E1669-77. PubMed ID: 25775566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting ryanodine receptors for anti-arrhythmic therapy.
    McCauley MD; Wehrens XH
    Acta Pharmacol Sin; 2011 Jun; 32(6):749-57. PubMed ID: 21642946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.
    Watanabe H; Chopra N; Laver D; Hwang HS; Davies SS; Roach DE; Duff HJ; Roden DM; Wilde AA; Knollmann BC
    Nat Med; 2009 Apr; 15(4):380-3. PubMed ID: 19330009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.
    van der Werf C; Kannankeril PJ; Sacher F; Krahn AD; Viskin S; Leenhardt A; Shimizu W; Sumitomo N; Fish FA; Bhuiyan ZA; Willems AR; van der Veen MJ; Watanabe H; Laborderie J; Haïssaguerre M; Knollmann BC; Wilde AA
    J Am Coll Cardiol; 2011 May; 57(22):2244-54. PubMed ID: 21616285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The direct actions of flecainide on the human cardiac ryanodine receptor: keeping open the debate on the mechanism of action of local anesthetics in CPVT.
    Smith GL; MacQuaide N
    Circ Res; 2015 Apr; 116(8):1284-6. PubMed ID: 25858058
    [No Abstract]   [Full Text] [Related]  

  • 20. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.
    Belardinelli L; Liu G; Smith-Maxwell C; Wang WQ; El-Bizri N; Hirakawa R; Karpinski S; Li CH; Hu L; Li XJ; Crumb W; Wu L; Koltun D; Zablocki J; Yao L; Dhalla AK; Rajamani S; Shryock JC
    J Pharmacol Exp Ther; 2013 Jan; 344(1):23-32. PubMed ID: 23010360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.